Morgan Stanley
TCON

Morgan Stanley’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Morgan Stanley’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10
Closed -$35 – 8012
2023
Q4 		$35 Buy
+10
New +$35 ﹤0.01% 7575
2023
Q1 		– Hold
0
– -$10 – 7865
2022
Q4 		– Hold
0
– – – 7801
2022
Q2 		– Sell
-97
Closed -$5K – 8068
2022
Q1 		$5K Buy
97
+27
+39% +$1.36K ﹤0.01% 7597
2021
Q4 		$4K Sell
70
-1,165
-94% -$74.3K ﹤0.01% 7704
2021
Q3 		$96K Buy
1,235
+659
+114% +$55.8K ﹤0.01% 6406
2021
Q2 		$75K Sell
576
-624
-52% -$86.3K ﹤0.01% 6477
2021
Q1 		$198K Sell
1,200
-7,878
-87% -$1.52M ﹤0.01% 5664
2020
Q4 		$2.12M Buy
+9,078
New +$1.26M ﹤0.01% 4103
2020
Q3 		– Sell
-56
Closed -$2K – 6861
2020
Q2 		$2K Hold
56
– – ﹤0.01% 6472
2020
Q1 		$2K Buy
+56
New +$3.25K ﹤0.01% 6412
2019
Q4 		– Sell
-7
Closed -$1K – 6810
2019
Q3 		$1K Sell
7
-3
-30% -$308 ﹤0.01% 6588
2019
Q2 		$1K Buy
10
+3
+43% +$474 ﹤0.01% 6585
2019
Q1 		$2K Hold
7
– – ﹤0.01% 6479
2018
Q4 		$1K Hold
7
– – ﹤0.01% 6534
2018
Q3 		$3K Buy
+7
New +$3.24K ﹤0.01% 6530
2017
Q3 		– Hold
0
– – – 6640
2017
Q2 		– Hold
0
– – – 6673
2016
Q4 		– Sell
-15
Closed -$20K – 6580
2016
Q3 		$20K Buy
15
+7
+88% +$7.89K ﹤0.01% 5915
2016
Q2 		$7K Buy
+8
New +$10.6K ﹤0.01% 6155
2015
Q4 		– Sell
-1
Closed -$3K – 6832
2015
Q3 		$3K Buy
+1
New +$2.34K ﹤0.01% 6458
2015
Q2 		– Sell
-11
Closed -$31K – 6779
2015
Q1 		$31K Buy
+11
New +$28.9K ﹤0.01% 5947

Other funds holding TCON

LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Morgan Stanley's TCON Position: Q1 2024 in Review

Morgan Stanley sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2024, closing a stake of 10 shares — an estimated $35 sold.

Morgan Stanley first reported a position in TCON in Q1 2015 and held it in 18 quarters. The position peaked at $2.12M in Q4 2020. 29 funds tracked by Wall St. Rank hold TCON as of Q1 2024.

  • Morgan Stanley reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Morgan Stanley sold 10 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $35.
  • Morgan Stanley first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 18 quarters.
  • Morgan Stanley's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $2.12M in Q4 2020.
  • 29 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.